Neurogenic Bladder Clinical Trial
Official title:
Retrospective Study With Botulinic Toxin in Neurogenic Detrusor Overactivity
Aims of this study were to assess the long-term outcomes of detrusor injection of OnabotulinumtoxinA (Botox® injection) associated with clean intermittent-catheterization (CIC) for the treatment of neurogenic detrusor overactivity (NDO) and to identify risk factors for failure.
Neurogenic detrusor overactivity (NDO) remains a major concern for patients with
neurological diseases. Fifty to eighty percent of patients with multiple sclerosis (MS) or
traumatic spinal cord injury (SCI) and more than 60% of patients with myelomeningocele
suffer from urinary incontinence episodes (UI) due to NDO. NDO is characterized by
involuntary detrusor contractions during the filling phase, leading to leakage and increase
in bladder pressure, which can, precipitate renal failure. Detrusor injection of
OnabotulinumtoxinA (Botox®), is licensed worldwide and recommended as a second line therapy
for the treatment of urinary incontinence due to NDO after failure of anticholinergic drugs
(Grade A).
These recommendations are based on the results of international multicentric, randomized
controlled trials.
These studies established not only clinical benefits, with a significant decrease of urinary
incontinence episodes, but also urodynamic benefits.
There are very few data about the real prevalence of failure of Botox® in the long term.
Thus, aims of this study were to assess the long-term outcomes of detrusor injections of
Botox® associated with clean intermittent-catheterization (CIC) for the treatment of NDO and
to identify risk factors for failure .
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT02978638 -
Electrical Stimulation for Continence After Spinal Cord Injury
|
N/A | |
| Enrolling by invitation |
NCT06429631 -
The Effect of CIC Education on QOL and Compliance With Mobile Application in Individuals With Spinal Cord Injury.
|
N/A | |
| Completed |
NCT03573726 -
Use of a Diurnal Indwelling Urethral Catheter to Improve Quality of Life
|
N/A | |
| Recruiting |
NCT06059066 -
Optimization of OnabotulinumtoxinA (BTX-A) Injection for the Treatment of Neurogenic Lower Urinary Tract Dysfunction
|
N/A | |
| Completed |
NCT01429090 -
Bioavailability of Vagantin® Coated Tablets Relative to an Oral Methantheline Bromide Solution
|
Phase 1 | |
| Recruiting |
NCT05587101 -
Neurogenic Lower Urinary Tract Symptoms in Patients With Multiple Sclerosis
|
||
| Terminated |
NCT03843073 -
Connected Catheter- Safety and Effectiveness Study
|
N/A | |
| Terminated |
NCT04059159 -
Connected Catheter - Safety and Effectiveness Study
|
N/A | |
| Completed |
NCT05861024 -
Urinary Calculi After Bladder Augmentation in Children
|
||
| Completed |
NCT05858840 -
Urinary Artificial Sphincter in Children
|
||
| Completed |
NCT04074616 -
Reducing Anticholinergic Bladder Medication Use in Spinal Cord Injury With Home Neuromodulation
|
N/A | |
| Completed |
NCT05683938 -
GentleCath™ Air Intermittent Catheter Smartwatch Real Life Pilot Study
|
||
| Completed |
NCT04543552 -
A Comparative Analysis of Portable Bladder Scanner to Determine Age/ Volume Specific Accuracy in 0-6 Years of Children
|
||
| Active, not recruiting |
NCT06247033 -
Efficacies of Different Managements in Patients With Overactive Bladder With Stroke
|
N/A | |
| Withdrawn |
NCT01305681 -
Bacterial Properties With LoFric® Catheters During Clean Intermittent Catheterization
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04248322 -
Qualitative Assessment of the Impact of TTNS on QOL and Participation
|
||
| Recruiting |
NCT05301335 -
Spinal COrd NeuromodulaTor by SpIneX and ScoNE to Treat NeurogeniC BladdEr - SCONE "CONTINENCE" Clinical Study
|
N/A | |
| Recruiting |
NCT04924569 -
Continence Care Registry
|
||
| Completed |
NCT01716624 -
Botox Versus Oxybutynin as First Line Treatment for the Poorly Compliant Pediatric Neurogenic Bladder
|
Phase 3 | |
| Completed |
NCT01297647 -
Incidence of Urinary Tract Infection After Urodynamic Investigation
|
N/A |